{"name":"Corvus Pharmaceuticals","slug":"corvus","ticker":"CRVS","exchange":"NASDAQ","domain":"corvuspharma.com","description":"Corvus Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of various cancers. The company's pipeline includes several promising candidates, including CPI-006 and CPI-818. With a strong focus on oncology, Corvus aims to address significant unmet medical needs and improve patient outcomes.","hq":"Burlingame, CA","founded":0,"employees":"","ceo":"Richard Miller","sector":"Clinical-Stage Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$70M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":33719000,"netIncome":-15283000,"cash":4576000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"CPI-006 patent cliff ($0.00 at risk)","drug":"CPI-006","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"CPI-818 patent cliff ($0.00 at risk)","drug":"CPI-818","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CPI-444 Tablets","genericName":"CPI-444 Tablets","slug":"cpi-444-tablets","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CPI-444 Tablets","genericName":"CPI-444 Tablets","slug":"cpi-444-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Corvus Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, highlighting its progress in clinical development and operational efficiency.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"trial","headline":"Corvus Pharmaceuticals Announces Update on Phase 1/2 Clinical Trial of CPI-818","summary":"Corvus Pharmaceuticals provided an update on its Phase 1/2 clinical trial of CPI-818, a CD47-targeting antibody, in patients with relapsed or refractory multiple myeloma.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"Corvus Pharmaceuticals Enters into Agreement with National Cancer Institute","summary":"Corvus Pharmaceuticals entered into an agreement with the National Cancer Institute to support the development of its CPI-006 program.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQS2poc1g4TnJlb0NDblk1TWxjbW5vTXBfNWZEQkotNGdzUmhaM3l2dFFlYTktbHh4ZzlTNzZtZ3F1dWVRQkRFMmVyT1pzYzdoQlFHbFR6WTVscXMycTN1U196MnpZWGVjRjVOT0FKZkthc2ZlMHd4VmQwRHpzQ0JQVXVjTHMwN0t4S0JuYjIxWHRfc1BPb0dKSk9aVVlpMVNDSlNsX0NwOFpSU1lwZFFIOXh0bGptdw?oc=5","date":"2026-03-13","type":"pipeline","source":"Stock Titan","summary":"Corvus Pharmaceuticals (NASDAQ: CRVS) launches $200M at-the-market stock program - Stock Titan","headline":"Corvus Pharmaceuticals (NASDAQ: CRVS) launches $200M at-the-market stock program","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSm15bm5tQngwd3NjRFY3dmxSMWFWV2llelRra2xpblBHS1BkVm5mNndnWHNJNEhoUUNSM0lqZUlCVXVyYVJSRnRnbnRKM3VSdHIteHRLcnVGVDRCQ0xyRDdxMTJqQzUwdEFnTmxOSlNxcF83aE1tcHFPQmF4Ny1qZ204WUM2alJZbnU5bWhodU1HUU0zbmItY2huZm9XTW9veWI5cDlSOTgzZTVGbWxwTVZ6NTROU0FhUzBrcFJR?oc=5","date":"2026-03-12","type":"regulatory","source":"Stock Titan","summary":"Corvus eczema drug posts positive early data and $189M cash boost - Stock Titan","headline":"Corvus eczema drug posts positive early data and $189M cash boost","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNS01ZNEtTeGtuWTFNYWlXQWVDY180Tjc1a1F3MFFRQXZxSUFIdlJnQldZZGxWcjZMVEE2dHVBd3lSTlRNUjF3ZGJUOTBqOTFRSjcwa1ctVGdOekNtYmxSektkLWtoRXZwWE9FNHFwV095b2M3dXk1Yl8xTGExM1JVYXRlcVBzYlFG?oc=5","date":"2026-01-24","type":"trial","source":"Yahoo Finance","summary":"Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans - Yahoo Finance","headline":"Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPT09sU21ZWFd6YTA2MmllakdXdUwweU11cWVVbldrQ0gxRjlabUFpcUpwN2VjWjhwYmdScHZiUHF0Q3NkelZGdXl2S1BsMmdDa3BWV3pwN1RWalRnNFg3UEwtTXZjQjBoSGxuU296WEFMNEFJNENuWUFMUXFWbi1va0p4ZVRoX2V4SHlTaGQ3ZFUtRF9qcXctNUxGc3psM3lkaExlVFZKbWpOblRYdm5JQm9oeEhOOF9UQ2p3dlZhdw?oc=5","date":"2026-01-23","type":"trial","source":"Stock Titan","summary":"Corvus Pharma raises $201M to support cancer and skin trials - Stock Titan","headline":"Corvus Pharma raises $201M to support cancer and skin trials","sentiment":"neutral"},{"date":"2026-01-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"pipeline","source":"The Manila Times","summary":"Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times","headline":"Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPaEpqZEpPaUo4MWxTUWQ2bEJ1cUZKbHRYRUplcGpUaWVkS0lVT2VJU29yRHo3dmpCRzFUaHlrNnYtaENfcFgtMVI5ZmR1Q19KdVltbEhJaTlNSXU1MDBNTDcxSEFKUjRRX1ZxYUxvZ1pnVlJLX1BsRFoyMFF3VW9LNWIzWFhZM0tRR0NCQW9jYU4tWUVsNDNlZ3piY1JhNG9nM0M4NGhJTGtodjNFUzFQWi0tRXFIZnZlQklmUg?oc=5","date":"2026-01-21","type":"trial","source":"Seeking Alpha","summary":"Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know (CRVS) - Seeking Alpha","headline":"Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know (CRVS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNNGNDM3JsYVV0dmpQeE5DWjBtcmlVazBpTm1DSk5sSkNmbTFPS2RtWmF1bjVtcDBQUXpfQzhtV2JGQ3ZGTkZlZ2JjMkVRQjVuQS1rMG93NGYta2RtR0VzeHZqRHdOZWlvQ25jaFJ1QTNSOVhpQmt6ZHJrWWd4LVE0emY1dXBVZVNoTElfeEY4ejJOVGI5RWhMTzBBVjFMc1Q2WU5rTkJrclMtZnRJRnNDUmpkQTh3OVFsNW9YakhsZHJSLUxPMlMyUDRlUEEyMHc?oc=5","date":"2026-01-21","type":"pipeline","source":"GuruFocus","summary":"Corvus Pharma (CRVS) Maintains \"Outperform\" Rating, Price Target Doubles | CRVS Stock News - GuruFocus","headline":"Corvus Pharma (CRVS) Maintains \"Outperform\" Rating, Price Target Doubles | CRVS Stock News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOTjlYZmZIUk1mZGhxbjhuSmZvbEZHNWI1UHMyZE5DMjI1cWROMVc5UUNpd3EwR2dpV29VM0ZBN21RNHVoc2U2VWdzdW82d2ZvN2lGaEdDRUhIc2xCdXJfUVM0M3RLTDZYd3hmUnV1dkE0U3ZORTFnaEI4VmZ5NUt1ZjhidUFFNDloMW16aHFRYXEyaUFlWXhqQ19zWDQ?oc=5","date":"2026-01-20","type":"pipeline","source":"Investor's Business Daily","summary":"Why Small Biotech Stock Corvus Pharma Just Launched To A Nine-Year High - Investor's Business Daily","headline":"Why Small Biotech Stock Corvus Pharma Just Launched To A Nine-Year High - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPOUtvZ2VKbHNUV3I2QnJGdHFQMXpkRS1kM3hXNkZsLUdLUmtWSk10MTYxTE85X21IZHVXajdYQUZLR2JqTG5MT2VycTRtc3oycmlxQ0VidWtMUHhXa2VTdjBYOVFUY21EZGtoa3A2WE56V2VzdEp6X0JheEVyQURDYkxQU2xxR1J4b3hzZkhyWWcyUDZEVmw0RUF1VGNQd3JTajNxM0h6Q3hKeWhOcFMzd2VLRmZxdmgtczNwWjVvZWMyYnc?oc=5","date":"2026-01-20","type":"pipeline","source":"Investing.com","summary":"Corvus Pharma stock falls after announcing $150 million offering - Investing.com","headline":"Corvus Pharma stock falls after announcing $150 million offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNNnRsZ01HM0FQMF9sdFVOYllWaFFHWlJ0M2FiNnBFVGRyeG8wWTNoVXlTcXdSSmI0V0UzaE1hMkRRdkVWS2tUVm5TV2c2ZUpDNENZUnh1NVN0U1I1N1hHMFExWldjWWVTcGlQeVRWVXd0Z00yclJkMVc4OGZ4UEhDc1dBV3JPbkNnam5PLWRMUDZ4QUZaYy1uQ3R4MFk2bXd3MkZGZWtRQWJtR1pFaTVyQnlGWkYwQQ?oc=5","date":"2026-01-20","type":"regulatory","source":"Stock Titan","summary":"Corvus eczema drug improves key symptoms for 75% in early trial - Stock Titan","headline":"Corvus eczema drug improves key symptoms for 75% in early trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNUxhenVxXzNFZkNTRndabk4tdmVES2o3UFRhcThhdUV0a19sbE1OMEVRaXphanZfSWlVNUxPcTVGOC1ISWgxWEFZQkR4MTlDbTk1M3RPamZxUjBVd1BQcnh2X3lPNFZ5bURkWXZsWUZGMW5hOWY1U2VGY3ZRZFByeTZpWmQtdjYwb01qMUY0R3huY1ZpemI0SDU4M0g0TEFfZllJVkszeHVJUDhmQmpkSEFKWDg1NGEzNnlBdW5uTQ?oc=5","date":"2026-01-20","type":"trial","source":"Stock Titan","summary":"Corvus Pharma seeks $150M for lymphoma, skin trial work - Stock Titan","headline":"Corvus Pharma seeks $150M for lymphoma, skin trial work","sentiment":"neutral"}],"patents":[{"drugName":"CPI-006","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"CPI-818","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":33719000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-15283000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":4576000,"cashHistory":[],"totalAssets":71119000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}